
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. is positioned for significant commercial momentum, anticipated to accelerate markedly in 2026, with a potential pathway to achieving cash flow-positive status before the midpoint of that year. The company has demonstrated strong performance with its product Auvelity, which has exceeded sales expectations, and there is a heightened probability of regulatory approval for AXS-05, now revised to 85%, following the FDA's designation of priority review. Additionally, expectations are optimistic regarding market penetration for AXS-05, reflecting the overall belief in its potential to provide meaningful advancements for patients with CNS disorders.
Bears say
Axsome Therapeutics faces significant challenges that contribute to a negative outlook on its stock, particularly regarding expected market access for its product AUVELITY, which may fall short of projections. The company is also at risk from potential setbacks in clinical trials for key products, such as AXS-05 and solriamfetol, along with delays in securing necessary approvals for additional pipeline candidates like AXS-12 and AXS-14. Furthermore, there are concerns about the competitive landscape and market penetration, which could lead to lower-than-anticipated commercial success and long-term dilution risks impacting investor sentiment.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares